Anti-KAT3A / CBP antibody [NM11] (Biotin) (ab79270)

Overview

  • Product nameAnti-KAT3A / CBP antibody [NM11] (Biotin)
    See all KAT3A / CBP primary antibodies
  • Description
    Mouse monoclonal [NM11] to KAT3A / CBP (Biotin)
  • ConjugationBiotin
  • Specificityab79270 recognizes KAT3A as well as CBP. KAT3A and CBP differ by three noncontiguous residues within the 21 amino acid epitope region, a difference that does not detectably affect the reactivity of the antibody.
  • Tested applicationsSuitable for: IHC-P, ICC/IFmore details
  • Species reactivity
    Reacts with: Mouse, Rat, Human, Mink (Mustela), Monkey
  • Immunogen

    E1A affinity purified KAT3A protein.

  • EpitopeAmino acids 2071-2091
  • Positive control
    • Rat spleen and human tonsil tissues.

Properties

Associated products

Applications

Our Abpromise guarantee covers the use of ab79270 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-P
ICC/IF
  • Application notesICC/IF: Use at an assay dependent dilution.
    IHC-P: 1/50 - 1/100 for 20-30 minutes at room temperature depending on detection system.
    Staining of formalin fixed tissues requires boiling tissue sections in 10mM citrate buffer, pH 6.0, for 10-20 minutes followed by cooling at room temperature for 20 minutes.

    Not yet tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • Target

    • FunctionAcetylates histones, giving a specific tag for transcriptional activation. Also acetylates non-histone proteins, like NCOA3 coactivator. Binds specifically to phosphorylated CREB and enhances its transcriptional activity toward cAMP-responsive genes. Acts as a coactivator of ALX1 in the presence of EP300.
    • Involvement in diseaseNote=Chromosomal aberrations involving CREBBP may be a cause of acute myeloid leukemias. Translocation t(8;16)(p11;p13) with MYST3/MOZ; translocation t(11;16)(q23;p13.3) with MLL/HRX; translocation t(10;16)(q22;p13) with MYST4/MORF. MYST3-CREBBP may induce leukemia by inhibiting RUNX1-mediated transcription.
      Defects in CREBBP are a cause of Rubinstein-Taybi syndrome type 1 (RSTS1) [MIM:180849]. RSTS1 is an autosomal dominant disorder characterized by craniofacial abnormalities, broad thumbs, broad big toes, mental retardation and a propensity for development of malignancies.
    • Sequence similaritiesContains 1 bromo domain.
      Contains 1 KIX domain.
      Contains 2 TAZ-type zinc fingers.
      Contains 1 ZZ-type zinc finger.
    • DomainThe KIX domain mediates binding to HIV-1 Tat.
    • Post-translational
      modifications
      Methylation of the KIX domain by CARM1 blocks association with CREB. This results in the blockade of CREB signaling, and in activation of apoptotic response.
      Phosphorylated upon DNA damage, probably by ATM or ATR.
      Sumoylation negatively regulates transcriptional activity via the recruitment of DAAX.
    • Cellular localizationCytoplasm. Nucleus. Recruited to nuclear bodies by SS18L1/CREST. In the presence of ALX1 relocalizes from the cytoplasm to the nucleus.
    • Information by UniProt
    • Database links
    • Alternative names
      • CBP antibody
      • CBP_HUMAN antibody
      • CREB binding protein antibody
      • CREB-binding protein antibody
      • Crebbp antibody
      • Cyclic AMP responsive enhancer binding protein antibody
      • KAT3A antibody
      • RSTS antibody
      • RTS antibody
      • Rubinstein Taybi syndrome antibody
      see all

    References for Anti-KAT3A / CBP antibody [NM11] (Biotin) (ab79270)

    This product has been referenced in:
    • Dallas PB  et al. Characterization of monoclonal antibodies raised against p300: both p300 and CBP are present in intracellular TBP complexes. J Virol 71:1726-31 (1997). Read more (PubMed: 8995708) »
    • Dallas PB  et al. Monoclonal antibody NM11 recognizes a C-terminal epitope shared by p300 and CBP. Hybridoma 16:273-5 (1997). Read more (PubMed: 9219037) »

    See all 2 Publications for this product

    Product Wall

    Application Western blot
    Sample Mouse Cell lysate - whole cell (MEFs)
    Gel Running Conditions Reduced Denaturing (4-15%)
    Loading amount 30 µg
    Specification MEFs
    Blocking step Milk as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: RT°C
    Username

    Abcam user community

    Verified customer

    Submitted May 20 2015

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"